Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25567977 | 0.93 | KDM5A (0.43) | EPHX1EPHX2PARP1FPR3FPR2 | |
| SCHEMBL25567971 | 0.93 | KDM5A (0.43) | EPHX1EPHX2PARP1FPR3FPR2 | |
| SCHEMBL22892876 | 0.86 | CCR5 (0.52) | EPHX1EPHX2PARP1FPR3FPR2 | |
| SCHEMBL20970613 | 0.84 | EPHX1 (0.59) | EPHX1EPHX2MEN1KMT2A | |
| SCHEMBL25579558 | 0.84 | EPHX1 (0.45) | EPHX1EPHX2PARP1FPR3FPR2 | |
| SCHEMBL22892754 | 0.83 | LTA4H (0.45) | PARP1FPR3FPR2SMN1; SMN2 | |
| SCHEMBL27688983 | 0.81 | PARP1 (0.49) | EPHX1EPHX2PARP1FPR3FPR2 | |
| SCHEMBL25567991 | 0.81 | CHRM1 (0.46) | PARP1FPR3FPR2 | |
| SCHEMBL25570021 | 0.81 | EPHX2 (0.48) | EPHX1EPHX2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL12448078 | 0.80 | EPHX1 (0.49) | EPHX1EPHX2FPR2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | EPHX1 4433/4885EPHX2 4226/4885PARP1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.